Clinical Trials Directory

Trials / Unknown

UnknownNCT02361255

Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism

Status
Unknown
Phase
Study type
Observational
Enrollment
40 (estimated)
Sponsor
Corporal Michael J. Crescenz VA Medical Center · Federal
Sex
All
Age
40 Years – 89 Years
Healthy volunteers
Not accepted

Summary

Parkinson's disease (PD) and Drug-induced Parkinsonism (DIP) can be clinically indistinguishable and DIP sometimes represents "unmasking of underlying PD. The objective of this study is to determine the relationship of underlying Parkinson's disease (PD) to the incidence and clinical outcome in DIP using non-motor assessments as a marker for nigrostriatal degeneration. Research Design: This is a nested case-control design to investigate risk factors associated with the development of DIP and persistent Parkinsonism after antipsychotic (AP) withdrawal (a potential clinical marker of underlying PD). Target enrollment is 45 subjects. Methodology: We will examine objective olfactory function (via objective olfactory testing), other non-motor symptoms of PD (via standardized validated questionnaires), and motor findings (via clinical exam and quantitative gait analysis) in: 1) DIP patients (30 subjects) compared to AP-treated patients without Parkinsonism (15 subjects) and 2) patients with persistent Parkinsonism compared to those whose symptoms resolve in the DIP cohort followed prospectively after a change in AP treatment. Additionally, in patients where it was performed clinically, we will evaluate dopamine transporter SPECT imaging (DaTI) as a marker of nigrostriatal integrity examining the ability of qualitative and semi-quantitative analysis to distinguish between pharmacologic and degenerative Parkinsonism. We will also measure serum uric acid and Apolipoprotein A1, two putative biomarkers in early PD, and examine their relationship with clinical and radiologic status.

Conditions

Interventions

TypeNameDescription
OTHERno intervention

Timeline

Start date
2015-02-01
Primary completion
2019-02-01
Completion
2019-04-01
First posted
2015-02-11
Last updated
2018-04-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02361255. Inclusion in this directory is not an endorsement.